CATX vs PATH
Perspective Therapeutics Inc. (CATX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Perspective Therapeutics Inc. (CATX) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CATX revenue for 2023-09-30 was $2.2M. Net income was -$10.4M. Revenue was up 4.6% from 2023-06-30 to 2023-09-30. CATX currently screens at market cap $280.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CATX currently screens at market cap $280.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CATX and PATH stock pages for the full models.
Not investment advice.